trending Market Intelligence /marketintelligence/en/news-insights/trending/dgrrekqgppkpvzkpiduwng2 content esgSubNav
In This List

Zogenix epilepsy drug scores US FDA breakthrough therapy designation

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Zogenix epilepsy drug scores US FDA breakthrough therapy designation

Zogenix Inc.'s investigational drug, ZX008, received the U.S. Food and Drug Administration's breakthrough therapy designation to treat a rare form of epilepsy.

The designation is based on the results of a phase 3 trial that showed the drug was superior in treating seizures in children and young adults suffering from the Dravet syndrome.

Dravet syndrome is a type of epilepsy with seizures that are often triggered by hot temperatures or fever.

The designation is intended to expedite the development and review of the medicine.

The drug is considered an orphan drug in both the U.S. and Europe. It has also received the fast track designation in the U.S.

Emeryville, Calif.-based Zogenix is focused on developing therapies for patients with rare central nervous system conditions.